Ixekizumab for the treatment of psoriatic arthritis: an Italian multicentric retrospective observational study

Abstract Ixekizumab (IXE), an IL-17 A inhibitor, demonstrated efficacy in clinical trials in patients with psoriatic arthritis (PsA), and favorable data have emerged from real-world evidence studies on psoriasis as well. However, real-world data specific to PsA remain limited. This study aims to ass...

Descripció completa

Dades bibliogràfiques

Autors principals:	Stefano Gentileschi, Riccardo Terribili, Carla Gaggiano, Elisa Fiorentini, Laura Cometi, Cosimo Cigolini, Fabio Massimo Perrotta, Silvia Scriffignano, Luca Di Cato, Anna Panaccione, Laura Niccoli, Fabrizio Cantini, Maurizio Benucci, Francesca Li Gobbi, Andrea Delle Sedie, Antonio Vitale, Ennio Lubrano, Bruno Frediani, Serena Guiducci
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2026-02-01
Col·lecció:	Scientific Reports
Matèries:	Psoriatic arthritis Ixekizumab Interleukin-17 Real-world evidence
Accés en línia:	https://doi.org/10.1038/s41598-026-37835-x
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!